LAVA Therapeutics (LVTX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

LVTX Stock Forecast

LAVA Therapeutics stock forecast is as follows: an average price target of $6.00 (represents a 305.41% upside from LVTX’s last price of $1.48) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

LVTX Price Target

The average price target for LAVA Therapeutics (LVTX) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 305.41% upside from LVTX's last price of $1.48.

LVTX Analyst Ratings

Buy

According to 3 Wall Street analysts, LAVA Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for LVTX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

LAVA Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 28, 2024	Arthur He	H.C. Wainwright	$6.00	$1.88	219.15%	305.41%
Mar 20, 2024	Roger Song	Jefferies	$6.00	$3.07	95.44%	305.41%

Row per page

Go to

The latest LAVA Therapeutics stock forecast, released on Jun 28, 2024 by Arthur He from H.C. Wainwright, set a price target of $6.00, which represents a 219.15% increase from the stock price at the time of the forecast ($1.88), and a 305.41% increase from LVTX last price ($1.48).

LAVA Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$6.00
Last Closing Price	$1.48	$1.48	$1.48
Upside/Downside	-100.00%	-100.00%	305.41%

In the current month, the average price target of LAVA Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to LAVA Therapeutics's last price of $1.48. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jun 28, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 27, 2022	SVB Leerink	Outperform	Outperform	Hold
Sep 16, 2022	JMP Securities	-	Market Perform	Initialise

Row per page

Go to

LAVA Therapeutics's last stock rating was published by H.C. Wainwright on Jun 28, 2024. The company gave LVTX a "Buy" rating, the same as its previous rate.

LAVA Therapeutics Financial Forecast

LAVA Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Mar 21
Revenue	-	-	-	-	-	-	-	-	-	-	$2.64M	$15.26M	$468.00K	$1.00M	$1.78M	$921.00K
Avg Forecast	-	-	-	-	-	-	-	$2.17M	$22.91M	$573.05K	$232.32K	$255.97K	$777.17K	$567.37K	$322.64K	$9.26M
High Forecast	-	-	-	-	-	-	-	$2.17M	$22.91M	$573.05K	$232.32K	$255.97K	$777.17K	$567.37K	$322.64K	$11.11M
Low Forecast	-	-	-	-	-	-	-	$2.17M	$22.91M	$573.05K	$232.32K	$255.97K	$777.17K	$567.37K	$322.64K	$7.41M
# Analysts	-	-	-	-	-	-	-	2	2	1	1	1	13	13	7	15
Surprise %	-	-	-	-	-	-	-	-	-	-	11.36%	59.62%	0.60%	1.76%	5.52%	0.10%

LAVA Therapeutics's average Quarter revenue forecast for Jun 23 based on 1 analysts is $573.05K, with a low forecast of $573.05K, and a high forecast of $573.05K. LVTX's average Quarter revenue forecast represents a -78.29% decrease compared to the company's last Quarter revenue of $2.64M (Dec 22).

LAVA Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Mar 21
# Analysts	-	-	-	-	-	-	-	2	2	1	1	1	13	13	7	15
EBITDA	-	-	-	-	-	-	-	-	-	-	$-4.19M	$-3.86M	$-10.72M	$-10.73M	$-7.13M	$-16.39M
Avg Forecast	-	-	-	-	-	-	-	$-1.30M	$-13.75M	$-343.83K	$-139.39K	$-153.58K	$-466.30K	$-12.40M	$-193.58K	$-164.80M
High Forecast	-	-	-	-	-	-	-	$-1.30M	$-13.75M	$-343.83K	$-139.39K	$-153.58K	$-466.30K	$-9.92M	$-193.58K	$-131.84M
Low Forecast	-	-	-	-	-	-	-	$-1.30M	$-13.75M	$-343.83K	$-139.39K	$-153.58K	$-466.30K	$-14.87M	$-193.58K	$-197.76M
Surprise %	-	-	-	-	-	-	-	-	-	-	30.04%	25.11%	22.98%	0.87%	36.81%	0.10%

undefined analysts predict LVTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than LAVA Therapeutics's previous annual EBITDA (undefined) of $NaN.

LAVA Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Mar 21
# Analysts	-	-	-	-	-	-	-	2	2	1	1	1	13	13	7	15
Net Income	-	-	-	-	-	-	-	-	-	-	$-15.00M	$997.00K	$-7.92M	$-10.55M	$-7.46M	$-16.57M
Avg Forecast	$-12.50M	$-12.25M	$-13.97M	$-16.67M	$-7.11M	$-7.92M	$-8.33M	$-5.49M	$-10.72M	$-12.23M	$-15.65M	$-14.62M	$-21.46M	$-12.87M	$-54.36M	$-166.68M
High Forecast	$-12.50M	$-12.25M	$-13.97M	$-16.67M	$-7.11M	$-6.79M	$-8.33M	$-5.49M	$33.51M	$-12.23M	$-15.65M	$-14.62M	$-21.46M	$-10.30M	$-54.36M	$-133.35M
Low Forecast	$-12.50M	$-12.25M	$-13.97M	$-16.67M	$-7.11M	$-8.83M	$-8.33M	$-5.49M	$-54.96M	$-12.23M	$-15.65M	$-14.62M	$-21.46M	$-15.45M	$-54.36M	$-200.02M
Surprise %	-	-	-	-	-	-	-	-	-	-	0.96%	-0.07%	0.37%	0.82%	0.14%	0.10%

LAVA Therapeutics's average Quarter net income forecast for Dec 22 is $-15.65M, with a range of $-15.65M to $-15.65M. LVTX's average Quarter net income forecast represents a -1669.38% decrease compared to the company's last Quarter net income of $997.00K (Sep 22).

LAVA Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Mar 21
# Analysts	-	-	-	-	-	-	-	2	2	1	1	1	13	13	7	15
SG&A	-	-	-	-	-	-	-	-	-	-	$3.71M	$3.10M	$3.02M	$4.30M	$3.21M	$1.42M
Avg Forecast	-	-	-	-	-	-	-	$2.86M	$30.15M	$754.19K	$305.75K	$336.88K	$1.02M	$746.71K	$424.62K	$12.19M
High Forecast	-	-	-	-	-	-	-	$2.86M	$30.15M	$754.19K	$305.75K	$336.88K	$1.02M	$746.71K	$424.62K	$14.63M
Low Forecast	-	-	-	-	-	-	-	$2.86M	$30.15M	$754.19K	$305.75K	$336.88K	$1.02M	$746.71K	$424.62K	$9.75M
Surprise %	-	-	-	-	-	-	-	-	-	-	12.15%	9.19%	2.95%	5.76%	7.57%	0.12%

LAVA Therapeutics's average Quarter SG&A projection for Jun 23 is $754.19K, based on 1 Wall Street analysts, with a range of $754.19K to $754.19K. The forecast indicates a -79.69% fall compared to LVTX last annual SG&A of $3.71M (Dec 22).

LAVA Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Dec 22	Sep 22	Jun 22	Mar 22	Sep 21	Mar 21
# Analysts	-	-	-	-	-	-	-	2	2	1	1	1	13	13	7	15
EPS	-	-	-	-	-	-	-	-	-	-	$-0.58	$0.04	$-0.31	$-0.41	$-0.29	$-0.65
Avg Forecast	$-0.47	$-0.46	$-0.52	$-0.62	$-0.27	$-0.30	$-0.31	$-0.20	$-0.40	$-0.46	$-0.58	$-0.55	$-0.80	$-0.37	$-2.03	$-8.14
High Forecast	$-0.47	$-0.46	$-0.52	$-0.62	$-0.27	$-0.25	$-0.31	$-0.20	$1.25	$-0.46	$-0.58	$-0.55	$-0.80	$-0.37	$-2.03	$-6.52
Low Forecast	$-0.47	$-0.46	$-0.52	$-0.62	$-0.27	$-0.33	$-0.31	$-0.20	$-2.05	$-0.46	$-0.58	$-0.55	$-0.80	$-0.37	$-2.03	$-9.77
Surprise %	-	-	-	-	-	-	-	-	-	-	0.99%	-0.07%	0.39%	1.12%	0.14%	0.08%

According to 1 Wall Street analysts, LAVA Therapeutics's projected average Quarter EPS for Dec 22 is $-0.58, with a low estimate of $-0.58 and a high estimate of $-0.58. This represents a -1558.38% decrease compared to LVTX previous annual EPS of $0.04 (Sep 22).

LAVA Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
BNOX	Bionomics	$0.28	$6.00	2042.86%	Buy
PMVP	PMV Pharmaceuticals	$1.61	$18.00	1018.01%	Buy
XLO	Xilio Therapeutics	$0.92	$7.00	660.87%	Buy
ANTX	AN2 Therapeutics	$1.23	$8.75	611.38%	Buy
AVTE	Aerovate Therapeutics	$2.61	$13.00	398.08%	Hold
LVTX	LAVA Therapeutics	$1.48	$6.00	305.41%	Buy
ANEB	Anebulo Pharmaceuticals	$1.50	$6.00	300.00%	Buy
ACRV	Acrivon Therapeutics	$6.44	$21.83	238.98%	Buy
CCCC	C4 Therapeutics	$4.01	$13.50	236.66%	Buy
TIL	Instil Bio	$24.76	$78.25	216.03%	Hold
RZLT	Rezolute	$4.86	$13.50	177.78%	Buy
ELYM	Eliem Therapeutics	$5.11	$13.00	154.40%	Buy
ERAS	Erasca	$2.60	$6.50	150.00%	Buy
ASMB	Assembly Biosciences	$14.72	$35.50	141.17%	Buy
NXTC	NextCure	$1.29	$3.00	132.56%	Buy
ADAG	Adagene	$2.26	$5.00	121.24%	Buy
KRON	Kronos Bio	$0.87	$1.63	87.36%	Buy
ACHL	Achilles Therapeutics	$1.07	$2.00	86.92%	Buy
DSGN	Design Therapeutics	$5.57	$9.67	73.61%	Buy
EWTX	Edgewise Therapeutics	$31.98	$45.00	40.71%	Buy
IKNA	Ikena Oncology	$1.73	$1.33	-23.12%	Buy

LVTX Forecast FAQ

Is LAVA Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, LAVA Therapeutics (LVTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of LVTX's total ratings.

What is LVTX's price target?

LAVA Therapeutics (LVTX) average price target is $6 with a range of $6 to $6, implying a 305.41% from its last price of $1.48. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will LAVA Therapeutics stock go up soon?

According to Wall Street analysts' prediction for LVTX stock, the company can go up by 305.41% (from the last price of $1.48 to the average price target of $6), up by 305.41% based on the highest stock price target, and up by 305.41% based on the lowest stock price target.

Can LAVA Therapeutics stock reach $2?

LVTX's average twelve months analyst stock price target of $6 supports the claim that LAVA Therapeutics can reach $2 in the near future.

What are LAVA Therapeutics's analysts' financial forecasts?

LAVA Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.17M (high $2.17M, low $2.17M), average EBITDA is $-1.303M (high $-1.303M, low $-1.303M), average net income is $-28.854M (high $-27.722M, low $-29.76M), average SG&A $2.86M (high $2.86M, low $2.86M), and average EPS is $-1.076 (high $-1.034, low $-1.11). LVTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-55.391M (high $-55.391M, low $-55.391M), average SG&A $0 (high $0, low $0), and average EPS is $-2.065 (high $-2.065, low $-2.065).

Did the LVTX's actual financial results beat the analysts' financial forecasts?

Based on LAVA Therapeutics's last annual report (Dec 2022), the company's revenue was $19.39M, beating the average analysts forecast of $1.83M by 957.98%. Apple's EBITDA was $-33.718M, beating the average prediction of $-13.155M by 156.32%. The company's net income was $-31.907M, missing the average estimation of $-64.607M by -50.61%. Apple's SG&A was $14.12M, beating the average forecast of $2.41M by 485.53%. Lastly, the company's EPS was $-1.23, missing the average prediction of $-2.295 by -46.41%. In terms of the last quarterly report (Dec 2022), LAVA Therapeutics's revenue was $2.64M, beating the average analysts' forecast of $232.32K by 1036.38%. The company's EBITDA was $-4.187M, beating the average prediction of $-139K by 2903.80%. LAVA Therapeutics's net income was $-14.996M, missing the average estimation of $-15.647M by -4.16%. The company's SG&A was $3.71M, beating the average forecast of $305.75K by 1114.73%. Lastly, the company's EPS was $-0.58, missing the average prediction of $-0.583 by -0.57%